KPV, also known as Lys-Pro-Val or alpha-MSH(11-13), is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). It is composed of the amino acids lysine, proline, and valine. KPV can be synthesized using standard solid-phase peptide synthesis techniques, which allow for precise control over its sequence and purity. This peptide is of interest due to its potential therapeutic applications in modulating immune responses. Researchers have primarily focused on KPV's anti-inflammatory and immunomodulatory effects. Studies have shown that KPV can reduce inflammation in various models, including skin and intestinal inflammation. Its potential to modulate immune responses makes it a candidate for treating conditions like inflammatory bowel disease and other autoimmune disorders. The mechanism of action of KPV involves its interaction with melanocortin receptors, particularly MC1R and MC3R. These receptors are part of the G-protein-coupled receptor family and play a role in regulating immune responses and inflammation. By binding to these receptors, KPV can modulate signaling pathways that lead to reduced production of pro-inflammatory cytokines. Pharmacokinetic data on KPV is limited. Researchers have noted that peptides like KPV generally have short half-lives due to rapid degradation by proteases. The bioavailability of KPV by various routes is not well-documented, but peptides typically have low oral bioavailability. Current research on KPV is ongoing, with studies exploring its efficacy and safety in preclinical models. It is not yet approved for clinical use, and its regulatory status varies by region. As of now, KPV is primarily available as a research chemical, and its use is restricted to laboratory settings.